Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168
Executive Summary
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
You may also be interested in...
Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.
Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS
BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.
Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.